Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
03 Septiembre 2024 - 3:05PM
Business Wire
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage
biopharmaceutical company focused on rare respiratory diseases,
today announced that its management team will present at the H.C.
Wainwright 26th Annual Global Investment Conference on September
10, 2024 at 10:00am ET/7:00am PT. A live webcast of the
presentation will be available on Savara’s website at
www.savarapharma.com/investors/events-presentations/ and will be
archived for 90 days.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim nebulizer
solution, is an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240903510959/en/
Savara Inc. IR & PR Anne Erickson
(anne.erickson@savarapharma.com) (512) 851-1366
Savara (NASDAQ:SVRA)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Savara (NASDAQ:SVRA)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024